Prostaglandin analogues and mouse intraocular pressure: Effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 6, 2005, Pages 2006-2011

  Ota, Takashi ^a   Murata, Hiroshi ^a,b   Sugimoto, Ei Ichiro ^a,c   Aihara, Makoto ^a   Araie, Makoto ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Tokyo Metropolitan Institute of Gerontology   (Japan)

^c HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; LATANOPROST; PROSTAGLANDIN DERIVATIVE; PROSTANOID RECEPTOR; TAFLUPROST; TRAVOPROST; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER; ANTIHYPERTENSIVE AGENT; CLOPROSTENOL; DRUG DERIVATIVE; EYE DROPS; PROSTAGLANDIN F; PROSTAGLANDIN F2 ALPHA;

ANIMAL EXPERIMENT; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EVALUATION; FEASIBILITY STUDY; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; LIGHT DARK CYCLE; MALE; MOUSE; NIGHT; NONHUMAN; PRIORITY JOURNAL; TECHNIQUE; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; MOUSE STRAIN; TIME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CIRCADIAN RHYTHM; CLOPROSTENOL; DINOPROST; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INTRAOCULAR PRESSURE; MALE; MICE; MICE, INBRED STRAINS; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F; PROSTAGLANDINS F, SYNTHETIC; TIME FACTORS;

EID: 22144496503     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-1527     Document Type: Article

References (32)

1. Nakajima T, Matsugi T, Goto W, et al. New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull. 2003;26:1691-1695.
2. Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767-776.
3. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19:501-515.
4. Sharif NA, Williams GW, Kelly CR. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol. 2001;432:211-213.
5. Sharif NA, Davis TL, Williams GW. [3H]AL-5848 ([3H]9beta-(+)- Fluprostenol): carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol. 1999;51:685-694.
6. Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol. 2002;47:S34-S40.
7. Goh Y, Kishino J. Pharmacological characterization of prostaglandin-related hypotensive agents. Jpn J Ophthalmol. 1994;38:236-245.
8. Anthony TL, Pierce KL, Stamer WD, Regan JW. Prostaglandin F2 alpha receptors in the human trabecular meshwork. Invest Ophthalmol Vis Sci. 1998;39:315-321.
9. Anthony TL, Lindsey JD, Aihara M, Weinreb RN. Detection of prostaglandin EP(1), EP(2), and FP receptor subtypes in human sciera. Invest Ophthalmol Vis Sci. 2001;42:3182-3186.
10. Lindsey JD, Weinreb RN. Mechanism of prostaglandin action on uveoscleral outflow. In: Weinreb RN, Kitazawa Y, Krieglstein GK, eds. Glaucoma in the 21st Century. London: Mosby International; 2000:195-200.
11. Aihara M, Lindsey JD, Weinreb RN. Reduction of intraocular pressure in mouse eyes treated by latanoprost. Invest Ophthalmol Vis Sci. 2002;43:146-150.
12. Aihara M, Lindsey JD, Weinreb RN. Aqueous humor dynamics in mice. Invest Ophthalmol Vis Sci. 2003;44:5168-5173.
13. Crowston JG, Lindsey JD, Aihara M, Weinreb RN. Effect of Latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor. Invest Ophthalmol Vis Sci. 2004;45:3555-3559.
14. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103:138-147.
15. Aihara M, Lindsey JD, Weinreb RN. Twenty-four-hour pattern of mouse intraocular pressure. Exp Eye Res. 2003;77:681-686.
16. Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther. 2002;18:313-324.
17. Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother. 2002;36:504-511.
18. Savinova OV, Sugiyama F, Martin JE, et al. Intraocular pressure in genetically distinct mice: an update and strain survey. BMC Genet. 2001;2:12.
19. Boyd TA, McLeod LE. Circadian rhythms of plasma corticoid levels, intraocular pressure and aqueous outflow facility in normal and glaucomatous eyes. Ann NY Acad Sci. 1964;117:597-613.
20. Reiss GR, Lee DA, Topper JE, Brubaker RF. Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci. 1984;25:776-778.
21. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351-1358.
22. Gabelt BT, Gottanka J, Lütjen-Drecoll E, Kaufman PL. Aqueous humor dynamics and trabecular meshwork and anterior ciliary muscle morphologic changes with age in rhesus monkeys. Invest Ophthalmol Vis Sci. 2003;44:2118-2125.
23. Resul B, Stjernschantz J, Selen G, Bito L. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Ophthalmol. 1997;41:S47-S52.
24. 2α-isopropyl ester to latanoprost: a review of the development of Xalatan. The Proctor Lecture. Invest Ophthalmol Vis Sci. 2001;42:1134-1145.
25. Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther. 2004;26:84-91.
26. Sponsel WE, Paris G, Trigo Y, Pena M. Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma. Am J Ophthalmol. 2002;134:552-559.
27. Jampel HD, Bacharach J, Sheu WP, Wohl LG, Solish AM, Christie W. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol. 2002;134:863-871.
28. Kashiwagi K, Kanai N, Tsuchida T, et al. Comparison between isopropyl unoprostone and latanoprost by prostaglandin E(2)induction, affinity to prostaglandin transporter, and intraocular metabolism. Exp Eye Res. 2002;74:41-49.
29. Kashiwagi K, Iizuka Y, Tsukahara S. Metabolites of isopropyl unoprostone as potential ophthalmic solutions to reduce intraocular pressure in pigmented rabbits. Jpn J Pharmacol. 1999;81:56-62.
30. Thieme H, Stumpff F, Ottlecz A, Percicot CL, Lambrou GN, Wiederholt M. Mechanisms of action of unoprostone on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2001;42:3193-3201.
31. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci. 2003;44:715-721.
32. Sharif NA, Crider JY, Husain S, Kaddour-Djebbar I, Ansari HR, Abdel-Latif AA. Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J Ocul Pharmacol Ther. 2003;19:437-455.